Adma Biologics (ADMA) shares rallied 18.8% in the last trading session to close at $19.37. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 16.7% loss over the past four weeks.
ADMA Biologics announced that KPMG will now serve as the company’s new independent registered public accounting firm effective upon the filing of its quarterly report for the fiscal quarter ended Sep. 30, 2024. Investors cheered the news. The stock was hit last month after the company noted that CohnReznick resigned as the company’s independent registered public accounting firm.
This infectious disease drug developer is expected to post quarterly earnings of $0.13 per share in its upcoming report, which represents a year-over-year change of +1200%. Revenues are expected to be $107.25 million, up 59.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Adma Biologics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ADMA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Adma Biologics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Twist Bioscience (TWST), finished the last trading session 3% higher at $41.57. TWST has returned -5.7% over the past month.
For Twist Bioscience , the consensus EPS estimate for the upcoming report has changed -1% over the past month to -$0.73. This represents a change of +9.9% from what the company reported a year ago. Twist Bioscience currently has a Zacks Rank of #4 (Sell).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
Twist Bioscience Corporation (TWST) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.